Cognitive Impairments in Children With Epilepsy

Since the proportion of language and attentional difficulties in patients with epilepsy is recognized, both in the literature and in the clinical experience of practitioners, it is appropriate to propose a complete speech-language assessment of oral language and attention.This study investigates these impairments through the taking of specific tests.

The general objective of this study is to observe possible oral language and attention disorders in children with epilepsy, by age and etiology of epilepsy.

The objective of this work is to study therapeutic apheresis (including plasma exchange and immunoadsorption) among french neuropediatric tertiary centers and to prove that this treatment modality is effective and well tolerated in pediatric neurology diseases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epilepsy Syndrome Brain Diseases Central Nervous System Diseases Communicable Diseases Communication Disorders Disease Attributes Epilepsies, Partial Epilepsy Epilepsy, Generalized Epileptic Syndromes Infections Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurodevelopmental Disorders Neurologic Manifestations Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

3 year–15 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Uh Montpellier

Montpellier, 34295, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The subjects should :

Be at least 3 years old and at most 15 years old
Be French speaker
Be in a regular class
Have a diagnosis of epilepsy

Exclusion criteria

Subjects schooled in IEM
Subjects diagnosed with austim spectrum disorder
Subjects with a motor or visual handicap
Subjects with psychiatric disorders

Treatment and study plan

Primary outcomes

Score in the different tests assessing oral language

Time frame: day 1
Test assessing oral language :
- Oral naming of images
- Oral designation of images
- Morphosyntactic comprehension test
- Syntactic production test
The scores obtained in the various tests are organized into 7 classes:

Class 1 = percentiles less than 7 : "pathological" zone Class 2 = 7 to 20 percentiles : "fragile" zone / "weak" zone Class 3 = 21 to 38 percentiles : "low standard" zone Class 4 = percentiles 39 to 62 : "median standard" zone / expected average results for age or grade level Class 5 = 63 to 80 percentiles : "higher standard" zone Classes 6 and 7 = respectively 81 to 93 percentiles and percentiles greater than 93 : zone with results well above the norm for age or grade level.

Secondary outcomes

Score in the different tests assessing attention

Time frame: day 1
Tests assessing attention :
- Visual attention test
- Auditive attention test
The scores obtained in the various tests are organized into 7 classes:

Class 1 = percentiles less than 7 : "pathological" zone Class 2 = 7 to 20 percentiles : "fragile" zone / "weak" zone Class 3 = 21 to 38 percentiles : "low standard" zone Class 4 = percentiles 39 to 62 : "median standard" zone / expected average results for age or grade level Class 5 = 63 to 80 percentiles : "higher standard" zone Classes 6 and 7 = respectively 81 to 93 percentiles and percentiles greater than 93 : zone with results well above the norm for age or grade level.

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Interest of Speech Therapy in Children With Epilepsy: What Impairments of Cognitive Functions?

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Oct 28, 2021
Registry last updated: Apr 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed